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A major feature of Alzheimer’s disease is the accumulation of amyloid-b peptide (Ab) in the brain both
in the form of plaques in the cerebral cortex and in blood vessel as cerebral amyloid angiopathy (CAA).
Experimental models and human clinical trials have shown that accumulation of Ab plaques can be reversed
by immunotherapy. In this study, we hypothesized that Ab in plaques is solubilized by antibodies generated by
immunization and drains via the perivascular pathway, detectable as an increase in cerebrovascular Ab.
We have performed a follow up study of Alzheimer’s disease patients immunized against Ab42. Neuropatho-
logical examination was performed on nine patients who died between four months and five years after their
first immunization. Immunostaining for Ab40 and Ab42 was quantified and comparedwith that in unimmunized
Alzheimer’s disease controls (n=11).Overall, compared with these controls, the group of immunized patients
had approximately 14 times as many blood vessels containing Ab42 in the cerebral cortex (P_0.001) and seven
times more in the leptomeninges (P=0.013); among the affected blood vessels in the immunized cases, most of
them had full thickness and full circumference involvement of the vessel wall in the cortex (P=0.001), and in the
leptomeninges (P=0.015).There was also a significantly higher level of cerebrovascular Ab40 in the immunized
cases than in the unimmunized cases (cortex:P=0.009 and leptomeninges: P=0.002). In addition, the immunized
patients showed a higher density of cortical microhaemorrhages and microvascular lesions than the unimmu-
nized controls, though none had major CAA-related intracerebral haemorrhages.The changes in cerebral vas-
cular Ab load did not appear to substantially influence the structural proteins of the blood vessels.Unlike most
of the immunized patients, two of the longest survivors, four to five years after first immunization, had virtually
complete absence of both plaques and CAA, raising the possibility that, given time, Ab is eventually cleared
from the cerebral vasculature. The findings are consistent with the hypothesis that Ab immunization results
in solubilization of plaque Ab42 which, at least in part, exits the brain via the perivascular pathway, causing a
transient increase in the severity of CAA.The extent to which these vascular alterations following Ab immuni-
zation in Alzheimer’s disease are reflected in changes in cognitive function remains to be determined.
Keywords: Alzheimer’s disease; cerebral amyloid angiopathy; immunotherapy; vasculature
Abbreviations: Ab=amyloid-b peptide; CAA=cerebral amyloid angiopathy; iAD= immunized Alzheimer’s disease;
MSI=Microhaemorrhage Severity Index; SMA=smooth muscle actin
Received February12, 2008. Revised September 12, 2008. Accepted September 18, 2008
Introduction
Alzheimer’s disease is the commonest cause of cognitive
decline in ageing. According to the amyloid hypothesis
(Hardy and Selkoe, 2002), abnormal aggregation of the
amyloid-b peptide (Ab) in the brain triggers the down-
stream effects of tau aggregation, microglial activation,
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synaptic dysfunction and neuronal loss together ultimately
resulting in cognitive decline (Albert, 1996; Graham and
Lantos, 2002). Ab accumulates in the brain in the form of
extracellular aggregates in the cerebral cortex (plaques) and
in the walls of blood vessels as cerebral amyloid angiopathy
(CAA) (Graham and Lantos, 2002). Schenk and colleagues
demonstrated that active peripheral immunization with the
Ab42 peptide in a transgenic mouse model of Ab
deposition resulted in both prevention of plaque formation
and removal of existing plaques (Schenk et al., 1999).
Experimental studies of both active and passive Ab
immunization in transgenic mice have since confirmed
that removal of existing Ab plaques can occur (Bard et al.,
2000; Games et al., 2000; DeMattos et al., 2001; Wilcock
et al., 2004a), sometimes within a matter of days (Bacskai
et al., 2001; Wilcock et al., 2003) and that this is associated
with cognitive benefits (Janus et al., 2000; Morgan et al.,
2000; Dodart et al., 2002). Immunization strategies in mice
can also neutralize the Ab oligomers, which current
evidence suggests are a particularly neurotoxic form of Ab
(Klyubin et al., 2005; Lesne et al., 2006).
The first clinical trial of Ab immunization in Alzheimer’s
disease was initiated in 2000 by Elan Pharmaceuticals Inc.
to explore tolerability and immunogenicity of active Ab42
immunization (Bayer et al., 2005). In this study involving
80 patients with mild to moderate Alzheimer’s disease, 64
patients received active immunization with synthetic Ab42
(AN1792) and 16 patients received a placebo. During the 18
month study period, Ab antibodies were generated,
predominantly to the N terminus (Lee et al., 2005), by
50% of the patients receiving Ab42 (Bayer et al., 2005). In
a subsequent larger clinical trial (n= 372), an inflammatory
complication was identified in 6% of the patients which
halted the trial (Orgogozo et al., 2003). Despite this set-
back, post-mortem studies from patients in both trials
confirmed that plaque removal occurred in immunized
Alzheimer’s disease patients as predicted by the experi-
mental mouse models (Nicoll et al., 2003, 2006; Ferrer
et al., 2004; Masliah et al., 2005; Bombois et al., 2007).
A consistent feature of the published post-mortem cases
has been the persistence of Ab associated with the cerebral
vasculature i.e. cerebral amyloid angiopathy (CAA) despite
the reduction of Ab in the form of plaques (Nicoll et al.,
2003, 2006; Ferrer et al., 2004; Masliah et al., 2005). CAA is
the accumulation of amyloid—in this context, Ab—in the
walls of arteries and arterioles in the leptomeninges and
cerebral cortex (Vinters, 1987; McCarron et al., 1999). It
occurs commonly in ageing and is usually thought to be
asymptomatic. However, it can present with stroke as a
result of spontaneous major intracerebral haemorrhage
which is characteristically superficial (lobar) and may be
multiple or recurrent. Such haemorrhages have also been
observed in a mouse model of severe CAA (Winkler et al.,
2001). Very rarely, severe CAA is associated with a rapidly
progressive dementia, often accompanied by multifocal
microhaemorrhages (Yamada, 2000). Ab peptide exists in
two major forms differing in length at the C terminus by
two amino acids, Ab42 and Ab40, with Ab42 predominat-
ing in cortical plaques and Ab40 being the predominant
form in the vasculature (Roher et al., 1993; Gravina et al.,
1995). Recently, several mechanisms or pathways for Ab
elimination have been identified including: (i) enzymatic
degradation by neprilysin and/or insulin-degrading enzyme
(McDermott and Gibson, 1997; Iwata et al., 2000;
Hellstrom-Lindahl et al., 2008); (ii) low density lipoprotein
receptor-related protein 1 (LRP-1) mediated clearance of
Ab across the blood–brain barrier into the blood (Hyman
et al., 2000; Shibata et al., 2000); and (iii) clearance of Ab
by drainage along perivascular pathways with interstitial
fluid, blockage of which is postulated to be the cause of
CAA (Weller et al., 1998; Preston et al., 2003; Nicoll et al.,
2004; Carare-Nnadi et al., 2005).
In this study, we have explored the Ab associated with the
cerebral vasculature with the following hypotheses in mind:
(i) Ab immunization in Alzheimer’s disease results in an
increase in the severity of CAA as Ab plaques are solubilized;
(ii) this increases the amount of Ab42 in the vessel walls,
reflecting solubilisation and perivascular drainage of plaque-
derived Ab42; (iii) the increase in CAA severity is associated
with an increase in the number of microhaemorrhages; and
(iv) accumulation of vascular Ab influences the structural
proteins of the blood vessel wall.
Materials and Methods
Cases
We performed a clinical and neuropathological follow-up of
patients who were enrolled in the initial Elan Pharmaceuticals Inc.
trial of Ab42 immunization in Alzheimer’s disease (Holmes et al.,
2008). As part of the study, patients and their carers were invited
to consent to post-mortem neuropathology. The study received
ethical approval from Southampton and South West Hampshire
Local Research Ethics Committees (Reference No: LRC 075/03/w).
We obtained post-mortem brains for neuropathology from nine
patients, all of whom had received Ab42 plus adjuvant and who
died between 4 and 64 months after the first immunization dose
(Table 1). Assessment of pathology associated with dementia was
performed by examining histological sections of frontal, temporal,
parietal and occipital lobes, corpus striatum, thalamus, midbrain,
pons, medulla and cerebellum. Paraffin sections were stained with
haematoxylin and eosin (H&E), Luxol fast blue/cresyl violet and
modified Bielschowsky silver impregnation. Selected sections were
immunostained for Ab, tau and a-synuclein. In one case, the
neuropathological assessment indicated a diagnosis of progres-
sive supranuclear palsy, on the basis of neuronal tangles
predominantly in the brainstem and basal ganglia, sparse in
the cerebral neocortex and absent from the hippocampus; the
neuropathological diagnosis was supported on review of the
clinical records. In the remaining eight cases, designated
immunized Alzheimer’s disease, the distribution of tau pathology
was completely different, and typical of Alzheimer’s disease, with
predominantly cortical tangles and severe hippocampal involve-
ment. These cases therefore showed appearances consistent with
Alzheimer’s disease (Braak stage V/VI) in which Ab components
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of the pathology had been influenced by Ab immunization as
previously described (Nicoll et al., 2003, 2006) (Table 1).
Controls
Paraffin sections from archival cases of Alzheimer’s disease from
the neuropathology service in Southampton General Hospital were
used as unimmunized Alzheimer’s disease controls (n= 11). All
patients had a history of progressive dementia and satisfied
Consensus Criteria for Alzheimer’s disease (The National Institute
on Aging, 1997) (Table 2). In addition, a case with severe CAA-
associated dementia from the archives of Southampton General
Hospital was included as a positive control for assessment of the
CAA-associated microhaemorrhages.
Immunohistochemistry
Primary antibodies
For the purposes of this study, sections of superior and middle
temporal gyrus, middle frontal gyrus and cingulate gyrus were
immunostained with antibodies specific for Ab40 (clone 2G3) and
Ab42 (clone 21F12) provided by Elan Pharmaceuticals Inc. (USA)
(Johnson-Wood et al., 1997). Blood vessel wall components were
assessed by immunostaining for endothelial cells (CD31, clone
1A10, Novocastra, UK), collagen IV (clone Col-94, Sigma, UK),
laminin (rabbit anti-laminin, Sigma, UK) and smooth muscle
actin (SMA; clone 1A4, DakoCytomation, UK). Microvascular
lesions were characterized by immunohistochemistry for astrocytes
(GFAP, clone 6F2) and microglia/macrophages (CD68, clone
PG-M1), both antibodies from Dako (Glostrup, Germany).
Immunohistochemistry
The Alzheimer’s disease and immunized Alzheimer’s disease cases
were stained together in batches for each antibody. Immunohis-
tochemistry was performed using the appropriate antigen retrieval
methods for each primary antibody. Biotinylated secondary
antibodies, normal serum and avidin-biotin complex were from
Vector Laboratories (Peterborough, UK). Immunohistochemistry
was carried out by the avidin-biotin-peroxidase complex method
(Vectastain Elite ABC, UK) with 3,30 diaminobenzidine (DAB) as
chromogen and 0.05% hydrogen peroxide as substrate. All the
sections were dehydrated before mounting in DePeX (BDH
Laboratory Supplies, UK). Sections incubated in the absence of
the primary antibody were included as negative controls.
Quantification
All quantification was performed blinded to the experimental
group and identity of the cases and was performed on sections of
superior and middle temporal gyrus, middle frontal gyrus and
cingulate gyrus.
Table 1 Characteristics of immunized Alzheimer’s disease cases and Ab42 parenchymal load
Case Gender Age Parenchymal
Ab42
load (%)a
Braak
stageb
Dementia
duration
(years)
AN1792
dose (mg)b
Number of
injections
Mean antibody
response
(ELISA units)b
Survival time from
first immunization
dose (months)b
1 F 74 1.26 VI 6 50 5 1:119 20
2 M 83 3.12 V 11 50 3 51:100 4
3 M 63 5.67 VI 6 225 4 51:100 41
4 F 71 4.68 VI 10 225 8 1: 4072 44
5c M 79 0.75 n/a (PSP) 6 50 8 51:100 51
6 M 81 3.32 VI 7 50 8 1:1707 57
7 M 82 0.05 VI 6 50 8 1: 4374 60
8 M 63 0.36 VI 10 50 8 1: 6470 64
9 M 81 2.71 VI 11 225 7 1: 491 63
n/a=non-applicable.
aAb42 load in sections of superior and middle temporal gyrus, middle frontal gyrus and cingulate gyrus. bHolmes et al., Lancet 2008; 3172:
216^23. cCase not included in the statistical analysis.
Table 2 Characteristics of Alzheimer’s disease controls and Ab42 parenchymal load
Case Gender Age Parenchymal
Ab42 load (%)a
Braak stage Dementia duration
(years)
1 F 80 4.58 V 3
2 F 88 4.31 VI Several yearsb
3 F 72 4.32 VI 7
4 F 78 6.84 VI Several yearsb
5 M 73 4.53 VI Several yearsb
6 F 72 5.76 VI 1
7 F 85 5.25 VI 16
8 F 84 2.50 VI 5
9 F 65 5.71 VI Several yearsb
10 F 88 4.12 VI 5
11 M 79 5.86 V 8
aAb42 load in sections of superior and middle temporal gyrus, middle frontal gyrus and cingulate gyrus. bPrecise duration not known.
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Cerebral Amyloid Angiopathy
CAA severity was quantified in sections of the immunized and
unimmunized Alzheimer’s disease cases in the different regions of
cerebral cortex described above. The sections were immunostained
separately with either Ab42 or Ab40 antibodies. The immuno-
stained cortical vessels were counted (10 microscope objective)
using a graticule; the data are presented as a number of stained
cortical vessels per 10 fields of cortex. The stained leptomeningeal
blood vessels were counted (10 microscope objective) through-
out the section and the data presented as a percentage of the total
number of meningeal vessels in the section.
In addition, 2 degrees of severity of involvement of each blood
vessel wall by Ab accumulation were noted: (i) partial staining; or
(ii) full staining (i.e. staining of both the full thickness and the full
circumference of the blood vessel wall).
A42 plaque load
Plaque load (%) was quantified in the cerebral cortex in the same
Ab42 immunostained sections as those in which the CAA was
quantified. The percentage area of cortex stained for Ab42
(excluding the vascular staining) was measured using Image
J 1.37v software (developed by Wayne Rasband, NIH, USA).
Perl’s Prussian blue staining
The sections of frontal, temporal and cingulated gyrus were dewaxed,
rehydrated and treated for 10min with a freshly prepared Perl’s
reagent: 2% potassium ferrocyanide and 2% hydrochloric acid pre-
pared in distilled water. Then the slides were counterstained with
0.1% neutral red, dehydrated and mounted in DePeX.
Microhaemorrhages and microvascular lesions
Microhaemorrhages were assessed using sections stained with
Perl’s Prussian Blue stain for iron. The haemorrhages were
counted using a scoring system similar to that described in a
mouse model (Pfeifer et al., 2002). A score of 1 was given to a
cluster consisting of 1–3 detectable particles of haemosiderin,
a score of 2 to a cluster of 4–10 particles and a score of 3 to a
cluster of 10 or more detectable particles. The Microhaemorrhage
Severity Index (MSI) for each section was calculated as: number of
clusters cluster score. For each case the mean MSI is expressed
per 50 fields of cortex (10 objective).
Microvascular lesions, which could represent either old micro-
infarcts or old microhaemorrhages, were defined as microscopic
foci of cortical destruction associated with a microglial and
astrocytic reaction and were quantified in large whole hemisphere
H&E stained sections taken at the level of the mamillary bodies
and therefore including temporal, parietal and frontal lobes. The
data are expressed as the number of microvascular lesions per 50
fields of cortex (10 objective).
Collagen IV, laminin and SMA
Computerized image analysis was performed on sections immu-
nostained with antibodies specific for collagen IV, laminin and
SMA. For each antibody the number of stained vessels was
counted at 10 objective magnification in 15 consecutive fields
and separately in the underlying white matter, using Image J 1.37v
software. An average score for the protein load (pixels) per stained
vessel was obtained by dividing in each field the stained area (in
pixels) by the number of stained vessels.
CD31
The CD31 staining was analysed by use of Image J 1.37v on
images taken at objective magnification 20. Thirty vessels were
assessed per brain section and data are expressed as the percentage
of CD31 per stained vessel.
Statistical analysis
The distributions of Ab42 and Ab40 stained vessels were
summarized using geometric and arithmetic means and ranges,
and were found to be close to normally distributed after taking
logs: they were compared between unimmunized Alzheimer’s
disease and immunized Alzheimer’s disease groups on the log scale
uncontrolled and controlled for age and gender in an analysis of
covariance. Estimated differences between means of the stained
vessels on the log scale were back transformed to give ratios of
geometric means and their 95% confidence intervals (CI). P-plots
of the standardized residuals (not shown) from the analyses of
covariance on the log scale confirmed approximate normality. The
CAA severity as partial or full staining of the blood vessel wall for
Ab42 and Ab40 often resulted in zero values so that logs could
not be taken: levels were compared between unimmunized
Alzheimer’s disease and immunized Alzheimer’s disease groups
using exact Mann–Whitney U-test. Spearman’s correlation
between Ab42 and Ab40 levels were estimated and exact tests
carried out specific to the cortex and leptomeninges and each
group. The parenchymal Ab42 and the microhaemorrhages and
microvascular lesions were compared between the two groups
using exact Mann–Whitney U-test. The assessment of the vascular
proteins in grey and white matter were approximately normally
distributed and were compared between groups using two sample
t-tests. All statistical tests were carried out in SPSS 14.0.
Results
Quantification of cerebral amyloid
angiopathy
Case 5, which had a post-mortem neuropathological
diagnosis of PSP rather than Alzheimer’s disease, had very
little Ab in the cerebral vasculature, as would be expected
because CAA is not a feature of that disease. This case has
therefore been omitted from the subsequent analysis.
Overall, compared with the unimmunized Alzheimer’s
disease controls, the immunized Alzheimer’s disease group
had approximately 14 times as many blood vessels con-
taining Ab42 in the cerebral cortex (P50.001) and
approximately seven times more in the leptomeninges
(P= 0.013) (Fig. 1A and B, Table 3). In addition, sig-
nificantly more blood vessels contained Ab40 in the
immunized cases than in the unimmunized controls
(cortex: P= 0.009; leptomeninges: P= 0.002) (Fig. 1A
and B, Table 3). The increased levels of Ab42 and Ab40
were higher after controlling for age and gender and with
greater statistical significance (Table 3), suggesting that
these differences were not due to these demographic
factors. There was a correlation between Ab40 and
Ab42 in both the cortical and meningeal vasculature
in the immunized cases (cortex: r= 0.929, P= 0.002;
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leptomeninges: r= 0.857, P= 0.011) which was less strong
in unimmunized cases (cortex: r= 0.568, P= 0.072; lepto-
meninges: r= 0.656, P= 0.032) (Fig. 1C and D).
In addition to there being more blood vessels stained
for Ab in the immunized Alzheimer’s disease cases,
individual blood vessels were more severely affected
(Table 4). Most of the blood vessels in the immunized
cases had staining for Ab40 and Ab42 involving both
the full thickness and full circumference of the vessel
wall (Fig. 2), a finding which was relatively infrequent
in the unimmunized Alzheimer’s disease controls.
Compared with the controls, the immunized cases had
substantially greater numbers of blood vessels with Ab42
staining of full thickness and full circumference of the
vessel wall in both the cortex (P= 0.001) and in the
leptomeninges (P= 0.015).
Comparison of CAA and Ab42 plaque load
Although the number of cases available for study was small
for this type of analysis and there was variation both
between cases and between the different anatomical regions
Fig. 1 Quantification of Ab42 and Ab40 vascular load in the cerebrum of immunized Alzheimer’s disease (iAD) cases (n=8) and
unimmunized Alzheimer’s disease (AD) controls (n=11). For each graph, themean values SEM for the Alzheimer’s disease and immunized
Alzheimer’s disease groups are shown. In addition, the values for the individual immunized Alzheimer’s disease cases are plotted from left
to right in order of survival time since immunization (from 4 to 64 months) to show themarked variation. (A) In the cortex, the immunized
Alzheimer’s disease cases have a significantly higher density of vessels immunostained for Ab42 (P50.001) and Ab40 (P=0.009) compared
with Alzheimer’s disease controls. (B) In the leptomeninges, the immunized Alzheimer’s disease cases have a significantly higher proportion
of vessels immunostained for both Ab42 (P=0.013) and Ab40 (P=0.002) compared with Alzheimer’s disease controls. In the immunized
Alzheimer’s disease cases, there is a significant correlation between Ab42 and Ab40 in the cortex (P=0.002) (C) and the leptomeninges
(P=0.011) (D). One of the immunized patients in whom the neuropathological diagnosis was PSP rather than Alzheimer’s disease and was
excluded from the assessment of correlation.
Table 3 Comparison of vascular Ab42 and Ab40 staining in the cortex and leptomeninges by analysis of covariance
uncontrolled and controlled for age and gender
Alzheimer’s
disease (n=8)
immunized
Alzheimer’s
disease (n=11)
Uncontrolled Controlled for age and gender
iAD
AD geometric
means (CI)
P iADAD geometric
means (CI)
P
Cortex Ab42 0.056 (0.071) 0.02^0.21 0.808 (1.289) 0.10^3.02 14.44 (5.80^35.92) 50.001 14.70 (4.67^46.29) 50.001
Ab40 0.071 (0.134) 0.01^0.42 0.690 (1.416) 0.01^43.58 9.65 (1.92^48.61) 0.009 13.48 (1.70^107.13) 0.017
Leptomeninges Ab42 1.872 (3.385) 0.28^10.42 13.182 (25.603) 0.26-43.58 7.04 (1.61^30.77) 0.013 12.10 (1.81^80.96) 0.014
Ab40 2.786 (4.413) 0.23^11.30 19.042 (28.583) 1.43^63.69 6.84 (2.18^21.41) 0.002 13.76 (3.57^52.87) 0.001
Figures are geometric mean (arithmetic mean), min to max. AD=Alzheimer’s disease; iAD= immunized Alzheimer’s disease.
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of cerebral cortex within individual immunized cases, sub-
jective assessment of the histological appearance suggested
a time-course of events following immunization (Fig. 2).
Prior to immunization (i) Ab42 is located predominantly in
plaques with little Ab42 in the vasculature; then following
immunization (ii) plaques have a moth-eaten appearance
and abundant Ab42 is detectable in the vessel walls; (iii) at a
later stage, Ab42 plaques have been removed from the
cortex but a substantial quantity of Ab42 remains in the
walls of the vasculature; and in the final stage (iv) Ab42 has
been removed from both plaques and blood vessel walls.
This putative sequence of events is illustrated in sequence
in Fig. 2. The comparison between the parenchymal and
the vascular Ab42 shows a significant lower of parenchymal
Ab42 (P= 0.020) after immunization associated with a sig-
nificant higher level of vascular Ab42 (P50.001) (Fig. 2B).
Microhaemorrhages and microvascular
lesions
Haemosiderin clusters resulting from parenchymal micro-
haemorrhages were quantified in sections stained with Perl’s
stain for iron (Fig. 3A–C). The immunized Alzheimer’s
disease cases were compared with unimmunized Alzheimer’s
disease controls and an unimmunized patient who devel-
oped a rapidly progressive dementia associated with severe
CAA, in order to put the findings into the context of very
Fig. 2 (A) Illustration of the relative distribution of Ab42 in the parenchyma versus the vasculature at different times after Ab42 immu-
nization. In the unimmunized Alzheimer’s disease cases, almost all the Ab42 is in the form of plaques with very little in the vasculature.
Four months after immunization, there is relatively abundant vascular Ab42 in the presence of ‘moth-eaten’ plaques. At 20 months post-
immunization, vascular Ab42 involving the full thickness and full circumference of the blood vessel walls is observed with no parenchymal
Ab42. At 60 months post-immunization, there is little Ab42 either in plaques or vessels. Scale bar=50mm. (B) Quantification of paren-
chymal Ab42 and vascular Ab42 in Alzheimer’s disease and immunized Alzheimer’s disease cases.The immunized Alzheimer’s disease group
shows a significantly lower load of parenchymal Ab42 (P=0.020) and a significantly higher level of vascular Ab42 (P50.001).
Table 4 Analysis of the CAA severity assessed by immunostaining for Ab42 and Ab40 in the immunized Alzheimer’s disease
cases and Alzheimer’s disease controls
Cortex Leptomeninges
Alzheimer’s
disease (n=11)
immunized
Alzheimer’s
disease (n=8)
P Alzheimer’s
disease (n=11)
immunized
Alzheimer’s
disease (n=8)
P
Ab42 Partial 0.03 (0.04) 0.00^0.08 0.10 (0.10) 0.10^0.24 0.048 0.34 (1.34) 0.00^3.58 4.29 (4.99) 0.13^11.51 0.062
Full 0.02 (0.03) 0.00^0.12 0.83 (1.19) 0.02^2.78 0.001 0.97 (2.05) 0.00^8.47 24.95 (20.62) 0.13^41.69 0.015
Ab40 Partial 0.01 (0.02) 0.00^0.08 0.06 (0.06) 0.00^0.13 0.071 2.10 (1.45) 0.00^2.83 2.65 (4.09) 0.37^10.53 0.088
Full 0.10 (0.11) 0.00^0.33 1.27 (1.35) 0.00^3.11 0.004 1.43 (2.96) 0.00^11.30 21.83 (24.49) 0.00^61.22 0.021
Figures are median (mean), min-max.‘Partial’ =partial staining of the blood vessel wall for Ab; ‘Full’ = staining of both the full thickness and
full circumference of the blood vessel wall.
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severe symptomatic CAA. Very little Perl’s positive staining
was identified in the unimmunized Alzheimer’s disease cases
(MSI = 0.04). The mean MSI score for the immunized cases
was 1.01 (P= 0.021); however, there was considerable inter-
individual variation (median = 0.25). Case 9 had the highest
MSI, more than 100 times the severity of that in unim-
munized cases, but even excluding this case as a potential
outlier the relationship remained significant (P= 0.043). To
put the microhaemorrhage severity into context even case 9
had less than one-third of the MSI value in the CAA-
associated dementia case (6 versus 20 MSI per 50 fields.).
Microvascular lesions, foci of cortical parenchymal
damage which could have been due either to old
micro-infarcts or old microhaemorrhages from which the
iron pigment has been resorbed, were very infrequent in the
unimmunized Alzheimer’s disease controls. Five of the eight
immunized cases had microvascular lesions (Fig. 3E–J)
ranging from 0.05 to 0.54 lesions per 50 fields of cortex
(Fig. 4B); the median value of the immunized cases dif-
fered significantly from that of the unimmunized controls
(0.06 versus 0.00; P= 0.033).
Overall, the immunized Alzheimer’s disease cases with
the microhaemorrhages and microvascular lesions did not
differ from those without microhaemorrhages and micro-
vascular lesions in terms of either the CAA severity or
evidence of plaque clearance.
Fig. 3 Illustration of microhaemorrhages and microvascular lesions in the immunized Alzheimer’s disease cases. Microhaemorrhages
were assessed in sections stained with Perl’s stain for iron and classified as (A) score 1, (B) score 2 or (C) score 3, used to derive the
Microhaemorrhage Severity Index. IIllustration of a microvascular lesion, which could represent an old microhaemorrhage or an old
micro-infarct, in immunized Alzheimer’s disease case 1: (E and F) on H&E staining. Characterization of a microvascular lesion (G andH)
by the presence of abundant surrounding activated astrocytes (immunohistochemistry for GFAP) and (I and J) activated macrophages
within the lesion (immunohistochemistry for CD68). H&E=haematoxylin and eosin staining. Scale bar: (A^C and J)=50mm; (F and
H)=100mm; (E,G and I)=200mm.
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Effects on blood vessel wall structure
Four different proteins of the blood vessel wall (CD31,
SMA, laminin and collagen IV) were studied to investigate
whether the increase of Ab within the cerebral vasculature
following immunization influenced blood vessel wall
structure. Although subjective histological analysis sug-
gested higher vascular loads of laminin and SMA in some
immunized Alzheimer’s disease cases (Fig. 5), significant
differences between the unimmunized and immunized
groups were not achieved on quantification of the staining
(Table 5).
Discussion
Following active immunization of Alzheimer’s disease
patients with Ab42, there is considerable variability in the
response in terms of the pathological changes. The extent of
Ab plaque clearance is patchy and variable, correlating to
some extent with the time since the first immunization dose
and the mean Ab antibody response in the 18 months after
immunization (Holmes et al., 2008). Here, despite the
reduction in plaque load, we provide evidence of an
increase in the quantity of Ab associated with the
vasculature in the form of CAA. CAA was more severe in
both cerebrocortical and overlying leptomeningeal blood
vessels in the immunized Alzheimer’s disease cases. This
divergence, with a lower plaque burden and an increase in
CAA severity, has been clearly demonstrated in immunized
APP transgenic mice in which elegant time course studies
have shown that as plaques are removed the CAA severity
increases (Wilcock et al., 2004a; Prada et al., 2007). The
opportunity to observe such a time course is of necessity
limited in our human post-mortem series, but as the
Fig. 4 Quantification of microhaemorrhages and microvascular
lesions in the immunized Alzheimer’s disease cases and
Alzheimer’s disease controls. For each graph, the mean
values  SEM for the Alzheimer’s disease and immunized
Alzheimer’s disease groups are shown. In addition, the values
for the individual immunized cases are plotted to show the
marked variation. (A) Quantification of microhaemorrhages
assessed by Perl’s staining in the cerebral cortex shows
significantly more microhaemorrhages in immunized Alzheimer’s
disease versus Alzheimer’s disease (P=0.021), although there
is considerable variation among the immunized cases.
(B) Quantification of microvascular lesions assessed on
H&E stained sections in the cerebral cortex shows a
significant difference (immunized Alzheimer’s disease versus
Alzheimer’s disease, P=0.033), although there is also
considerable variation among the immunized Alzheimer’s
disease cases. The immunized Alzheimer’s disease cases are
arranged from left to right in order of survival time following
first immunization dose (from 4 to 64 months). In one of the
immunized patients the neuropathological diagnosis was PSP
rather than Alzheimer’s disease. MSI=microhaemorrhage
severity index.
Fig. 5 Illustration of immunostaining in the immunized
Alzheimer’s disease and Alzheimer’s disease cases for vascular
laminin in the grey matter (A and B) and in the white matter
(C and D) showing more in immunized Alzheimer’s disease.
Illustration of SMA in the vasculature of the white matter of the
immunized Alzheimer’s disease versus Alzheimer’s disease
(E and F) showing more in immunized Alzheimer’s disease.
Scale bar=100mm.
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sequence of images in Fig. 2A shows, it certainly appears
that this biological phenomenon is also relevant to
immunized human Alzheimer’s disease. The rise in CAA
severity accompanying the fall in plaque load is also
consistent with the hypothesis that plaque Ab is solubilized
by binding of the Ab antibody generated by the
immunization, allowing Ab to diffuse to the vasculature
and with the concept that one of the routes of elimination
of Ab from the brain involves diffusion along perivascular
basement membranes (Weller et al., 1998, 2008; Weller,
2005; Carare et al., 2008). Indeed, although not assessed in
our study, unusually high levels of soluble Ab have been
detected in the brains of two other Alzheimer’s disease
patients immunized with Ab42 (Patton et al., 2006).
However, our data do not exclude possibility that plaque-
associated Ab is degraded rather than ‘cleared’, and that
increases in CAA occur independently of what is occurring
with plaque-associated Ab. It is known that some plaque
clearance is due to phagocytosis by microglia (Schenk et al.,
1999; Nicoll et al., 2003, 2006; Wilcock et al., 2004b) which
is not likely to be relevant to changes in CAA. Other
possible mechanisms by which Ab derived from plaques
could be transported to the vasculature include: binding to
apoE (Nicoll et al., 2006), binding to immunoglobulins to
form immune-complexes (Bard et al., 2000) or as soluble
Ab diffusing through the neuropil (Patton et al., 2006).
There is evidence that apolipoprotein E (APOE) genotype
influences CAA in Alzheimer’s disease with more severe
CAA in APOE e4 carriers (Greenberg et al., 1995; Kalaria
et al., 1996; Premkumar et al., 1996; Chalmers et al., 2003).
However, the relationship between plaque load and CAA
severity in individuals with different APOE genotypes is
still unclear (Love et al., 2003). Some of the differences
observed between the unimmunized and immunized
Alzheimer’s disease cases in our study might therefore
have been due to different APOE genotypes. Due to ethical
and legal constraints, the APOE genotypes could not be
determined. This is a limitation of the study; however,
even if the APOE genotypes had been available, the
number of cases in this study would be too small to
reach definitive conclusions as to the influence of genotype.
In addition, the higher level of CAA severity in the immu-
nized Alzheimer’s disease group compared with the control
group is way beyond anything accountable for by any pos-
sible differences between the groups in APOE genotypes.
The difference in the pattern of Ab distribution is rein-
forced by the relatively low plaque loads in the immunized
group, despite the higher CAA severity (Fig. 2). Further-
more, cortical as well as leptomeningeal vessels show the
same effect after immunization whereas APOE genotype
has its major effect on capillaries (Olichney et al., 2000;
Thal et al., 2002).
We specifically studied the effects of immunization on
the distribution of Ab42 in relation to the vasculature, as in
Alzheimer’s disease Ab42 is predominantly located in
plaques with very little in the vasculature (Roher et al.,
1993; Gravina et al., 1995). Examination of the immunized
cases provided us with the opportunity to test the
hypothesis that solubilization of plaque Ab42 following
Ab42 immunization might specifically increase the amount
of Ab42 associated with the vasculature. Indeed, we did
find substantially more Ab42 associated with the vascula-
ture in the immunized patients. In some of the immunized
cases, this gave rise to the unusual images of full thickness,
full circumference staining of vessel walls for Ab42 in the
absence of Ab42 plaques in the surrounding cortical
parenchyma (Fig. 2). This extensive labelling of blood
vessels for Ab42 in the absence of plaques was not
detected in the unimmunized subjects and appears to
be a striking example of the changes prompted by the
immunotherapy. However, there was also an equally
substantial increase in the density of vessels containing
Ab40 with a strong correlation of Ab40 with Ab42, con-
sistent with the notion that in the cerebral vasculature
Ab42 acts as a seed to promote aggregation of Ab40
(Alonzo et al., 1998). This finding supports the idea that
active immunization with Ab42 peptide also solubilizes
Ab40 from the parenchyma (Nicoll et al., 2006; Patton
et al., 2006) as the antibodies generated are mainly directed
Table 5 Assessment of the vascular proteins in the white and grey matter of the immunized Alzheimer’s disease and
Alzheimer’s disease cases
Protein Alzheimer’s
disease (n=11)
Immunized
Alzheimer’s
disease (n=8)
iADAD
difference (95%CI)
P
%CD31/vessel Grey 28.4 (6.1) 27.9 (3.6) 0.5 (5.6^4.6) 0.847
White 31.5 (6.0) 30.2 (5.9) 1.4 (7.2^4.5) 0.631
SMA (px)/vessel Grey 850.7 (176.4) 944.9 (134.7) 94.1 (63.2^251.5) 0.224
White 888.4 (242.0) 1117.1 (284.6) 228.8 (26.5^484.0) 0.076
Laminin (px)/vessel Grey 246.4 (28.1) 271.8 (33.9) 25.4 (4.62^55.4) 0.092
White 362.3 (94.5) 436.4 (102.0) 74.1 (21.6^169.8) 0.121
Collagen IV (px)/vessel Grey 135.3 (19.0) 153.5 (30.2) 18.2 (5.5^42.0) 0.124
White 259.4 (43.7) 290.8 (98.5) 31.4 (52.8^115.6) 0.421
Figures are mean (SD).
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against the N-terminal part of the Ab peptide which is
shared by Ab40 and Ab42 (Lee et al., 2005).
There are two key variables which may influence the
response to immunization, firstly the time since first
immunization dose, which ranged in this series from
4 months to 5 years, and secondly the immune response
of the patient to the active immunization with Ab42
(Holmes et al., 2008). In the immunized Alzheimer’s
disease cases with a long survival time (5 years) and high
immune response (cases 7 and 8), both CAA and plaques
were virtually absent from the brain, raising the possibilities
that (i) the increase in CAA may be a transient
phenomenon; (ii) the kinetics of Ab clearance from the
parenchyma and from the vasculature may be different, as
observed with in vivo imaging in mouse experiments (Prada
et al., 2007); and (iii) complete clearance of Ab from the
parenchyma and the vasculature can occur (Prada et al.,
2007) in association with a strong immune response over a
prolonged time. Direct evidence for eventual clearance of
Ab from the vasculature following immunization is not
available from animal experiments, possibly due to the
timescale involved (5 years time post-immunization is
longer than the lifespan of a transgenic mouse). Therefore
this suggestion, based as it is on a small number of
immunized Alzheimer’s disease cases, remains somewhat
speculative.
As well as an increase in CAA severity following
immunization, we have identified evidence for an increase
in the density of cortical microhaemorrhages and micro-
vascular lesions. Consistent with our findings, an increase
in microhaemorrhages in a transgenic APP mouse model
with particularly severe CAA was observed following
immunization (Pfeifer et al., 2002). However, to put this
into context, it is important to note that the cortical
volume affected by microhaemorrhages, even in the most
severely affected case, is very low and considerably lower
than the natural disease of rapidly progressive dementia
with CAA-associated microhaemorrhages (11.24 clusters per
50 fields representing 0.35% of the parenchyma). Due to
uncertainty about the pathogenesis of the microhaemor-
rhages and the evolution of their histological appearance
over a period of several years, we also assessed the vascular
pathology by quantifying microvascular lesions, which may
represent either old microhaemorrhages or old micro-
infarcts. Microvascular lesions also occurred with a higher
density in the immunized Alzheimer’s disease group than
the Alzheimer’s disease controls.
Nevertheless, there was no correlation between the
severity of CAA and the number of microhaemorrhages
or microvascular lesions (data not shown). This is not
altogether surprising because we were limited in the
timepoints sampled and these features are likely to have
different dynamics. The CAA severity is that present at the
time the patient died, whereas the microhaemorrhages/
microvascular lesions are likely to be the result of the
history of vascular damage over the preceding months
or years. Our hypothesis about the dynamics of the process,
based on animal models, suggests that at an earlier stage,
while the plaques were being cleared from the brain that
patient may have developed a high level of CAA, and
consequently acquired the microvascular lesions at that
time. However, this is speculation and current limitations
in the assessment of these processes preclude direct testing
of this hypothesis in the human brain.
Severe CAA can present with a stroke due to a large lobar
intracerebral haemorrhage but no such pathology was
identified in the cases we have examined. Orgogozo et al.
(2003) examined the imaging scans of patients in the later
trial of active immunization with Ab42. There were two
patients in the immunized group and one in the placebo
group who developed a cerebral haemorrhage. One
haemorrhage in the immunized group was a deep
intracerebral haemorrhage and the other was lobar, of
typical CAA-type (Orgogozo et al., 2003). Therefore it
seems that major CAA-related haemorrhages are not a
common feature of the response of the Alzheimer’s disease
brain to Ab42 immunization.
In Alzheimer’s disease, a variety of morphological
alterations in the vasculature have been reported including
degeneration of the smooth muscle cells, atrophy of the
endothelial cells and a thickening and local disruption of
the basement membrane (Farkas and Luiten, 2001). In
addition, CAA is also characterized by loss of smooth
muscle cells in the vicinity of Ab deposits as well as changes
in the extracellular matrix proteins of the basement
membrane (Zhang et al., 1998). The increased severity of
CAA following immunization, even if only transient, may
accelerate the damage to the vasculature induced by the
disease. We investigated these possible consequences by
immunohistochemistry to assess endothelial cells and
smooth muscle cells as well as the main extracellular
matrix proteins of blood vessels.
The immunization did not appear to modify the
endothelial cells or collagen IV protein, despite both
being affected in Alzheimer’s disease (Kalaria and Hedera,
1995; Tian et al., 2006). However, following Ab immuniza-
tion, there was a trend of increasing in SMA and laminin
associated with the vasculature mainly in the white matter
as illustrated in Fig. 5. Such findings could reflect either
attempts at repair of the vessels or the effects of
inflammation associated with the immunotherapy (Eng
et al., 2004; Scolding et al., 2005; Nicoll et al., 2006). The
study was too small to obtain statistically significant
differences between the unimmunized and immunized
Alzheimer’s disease groups with respect to these proteins.
In conclusion, following active Ab42 immunization in
human Alzheimer’s disease, we demonstrated that a lower
plaque load is associated with an increase in cerebrovas-
cular Ab. According to the perivascular drainage hypo-
thesis, this may represent Ab that is being removed
from the brain. Specifically, there was a marked increase
in Ab42 in the vessels, consistent with the translocation of
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solubilized plaque Ab42 to the vasculature. The relative lack
of both plaques and CAA in the cases with the highest
immune response and longest survival time raises the
possibility that the process of clearance of Ab from the
brain can progress to completion. Currently, there are
ongoing clinical trials of both active and passive immuniza-
tion for Alzheimer’s disease using altered methodology
designed to avoid the unwanted inflammatory side effects
experienced with the initial trials. Our results suggest that in
these new trials there may also be an at least transient increase
in CAA as Ab is cleared from the brain. The effect of the
increased CAA on cognitive function remains unknown.
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